Bicara Therapeutics (NASDAQ:BCAX) Receives New Coverage from Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Bicara Therapeutics (NASDAQ:BCAX) in a research note released on Tuesday, Marketbeat Ratings reports. The firm issued an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Bicara Therapeutics’ FY2024 earnings at ($1.61) EPS.

A number of other equities research analysts also recently issued reports on the stock. Stifel Nicolaus began coverage on shares of Bicara Therapeutics in a report on Tuesday. They issued a buy rating and a $47.00 price target on the stock. Morgan Stanley began coverage on shares of Bicara Therapeutics in a report on Tuesday. They issued an overweight rating and a $35.00 price target for the company. Finally, TD Cowen began coverage on shares of Bicara Therapeutics in a report on Tuesday. They issued a buy rating on the stock.

Bicara Therapeutics Price Performance

Shares of BCAX opened at $19.41 on Tuesday. Bicara Therapeutics has a 52-week low of $18.33 and a 52-week high of $27.94.

Insider Transactions at Bicara Therapeutics

In related news, Director Ra Capital Management, L.P. acquired 1,833,000 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was bought at an average cost of $18.00 per share, with a total value of $32,994,000.00. Following the acquisition, the director now owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. The trade was a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Ra Capital Management, L.P. acquired 1,833,000 shares of Bicara Therapeutics stock in a transaction dated Monday, September 16th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the transaction, the director now owns 4,303,418 shares of the company’s stock, valued at $77,461,524. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder James E. Flynn acquired 70,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $1,260,000.00. Following the completion of the acquisition, the insider now owns 897,587 shares in the company, valued at $16,156,566. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.